

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

VOLUNTARY ANNOUNCEMENT

TWO CLINICAL STUDY RESULTS OF M701 SELECTED FOR PRESENTATION AT THE 2026 ASCO ANNUAL MEETING

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the latest business updates of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that two clinical study results of the Company’s core innovative bispecific antibody product (“**M701**”) have been successfully selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (the “**ASCO Annual Meeting**”). Among them, the Phase III clinical study results of M701 for malignant ascites have been selected for an oral presentation at the Clinical Science Symposium of the meeting; simultaneously, the Phase II clinical study results of M701 for malignant pleural effusion have been selected for a poster presentation at the meeting.

This is another important milestone for the M701 project on the international oncology academic stage, reflecting the continued attention and recognition that M701 has received from the international academic community in the field of malignant serous cavity effusion treatment.

The clinical research progress to be presented by the Company at this year's ASCO Annual Meeting includes:

PHASE III STUDY OF MALIGNANT ASCITES SELECTED FOR ORAL PRESENTATION

- **No.** : 104
- **Subject** : Phase III, multicenter, randomized, controlled open-label study of M701 in advanced epithelial tumors with malignant ascites
- **Presentation format**: Oral presentation
- **Presenter**: Xu Jianming, The First Medical Center of Chinese PLA General Hospital
- **Presentation Date**: May 31, 2026

An oral presentation is one of the most highly regarded academic presentation formats at the ASCO Annual Meeting, typically representing recognition by the conference of a study's clinical value, innovative significance, and academic impact. This selection further highlights the important clinical significance of M701 in the treatment of malignant ascites and also reflects the continuously growing international influence of this program.

PHASE II STUDY OF MALIGNANT PLEURAL EFFUSION SELECTED FOR POSTER PRESENTATION

- **No.** : 12061
- **Subject** : A prospective randomized controlled Phase II study of M701 in NSCLC-related MPE
- **Presentation format**: Poster presentation
- **Presentation Date**: May 30, 2026

This study focuses on patients with non-small cell lung cancer associated malignant pleural effusion, further demonstrating the application potential of M701 in different indications of malignant serous cavity effusion, and laying the foundation for subsequent clinical development and indication expansion.

CONTINUOUSLY FOCUSING ON UNMET CLINICAL NEEDS AND ADVANCING INNOVATION IN TUMOR SUPPORTIVE CARE

Malignant ascites and malignant pleural effusion are common and severe complications in patients with advanced tumors. They not only significantly affect patients' quality of life but also pose ongoing challenges to clinical treatment. Current treatment options remain relatively limited, and there is a clear unmet clinical need.

M701 is a recombinant anti-epithelial cell adhesion molecule (EpCAM) / cluster of differentiation 3 (CD3) bispecific antibody for injection, designed to kill tumor cells by redirecting T cells, thereby providing a new treatment option for patients with malignant serous cavity effusion. Focusing on the two major indications of malignant ascites and malignant pleural effusion, M701 has gradually established a clinical development strategy with differentiated advantages.

FURTHER INTERNATIONAL ACADEMIC RECOGNITION, FACILITATING GLOBAL DEVELOPMENT AND COLLABORATION EXPANSION

The simultaneous selection of these two research findings for the 2026 ASCO Annual Meeting not only serves as an important recognition of the clinical research progress of M701 but will also further enhance the visibility of the project within the global oncology community and industry. The Company will continue to advance the clinical development and international collaboration strategy for M701, with the expectation of bringing more innovative treatment options to patients worldwide.

ABOUT ASCO

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the most influential academic conferences in the global oncology field. Each year, it brings together oncology experts, clinical researchers, innovative pharmaceutical companies, and industry organizations from around the world to showcase the latest scientific achievements and clinical advancements in oncology. It serves as an important bellwether for international oncology academia and industry development.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that M701 will ultimately be successfully developed and marketed. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board,
Executive Director and Chief Executive Officer

Wuhan, PRC, April 23, 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.